Abbott Laboratories Com Stk NPV (NYSE:ABT)

CAPS Rating: 5 out of 5

Principal business is the discovery, development, manufacture and sale of a broad and diversified line of health care products. Company has four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products.

Results 1 - 20 of 315 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 7/19/2014 12:22:14 PM : Outperform Start Price: $38.32 ABT Score: +8.63

Div. (Yield) $0.88 (2.1%)

Recs

0
Member Avatar afewgoodstocks11 (24.34) Submitted: 7/15/2014 12:53:12 PM : Outperform Start Price: $32.89 ABT Score: +15.93

Div. (Yield) $0.88 (2.1%)
Current Yield . . . . . 2.66%

Recs

0
Member Avatar BadNewsBarry (21.77) Submitted: 7/15/2014 7:45:46 AM : Outperform Start Price: $41.52 ABT Score: +4.99

ONLY SOLID BIOTECH STOCK ON THE MARKET, TRADING NEAR ITS 52 WEEK HIGH BUT MAKING MAJOR MOVES, SHOULD CONTINUE TO RISE.

Recs

0
Member Avatar TerryFool (38.05) Submitted: 4/21/2014 8:37:47 AM : Outperform Start Price: $37.59 ABT Score: +9.97

INVEST LONG TERM, BUY@ 38 TP 41 CAPS 5

Recs

0
Member Avatar Dividends500 (90.63) Submitted: 4/3/2014 12:55:35 AM : Outperform Start Price: $37.95 ABT Score: +8.19

Dividends500 tracks the 200 strongest dividends in the S&P 500. To qualify as a strong dividend, the company must meet two simple requirements:

- A payout ratio below 50%
- An increasing dividend from the prior year

Because there are more than 200 dividend paying companies in the S&P 500 that meet these requirements, the qualifying companies with the largest dividend yields were chosen.

Dividends500 intends to test this FactSet article, which highlights these strong dividend paying companies and their outperformance versus the S&P 500 as a whole (Page 12).

http://www.factset.com/websitefiles/PDFs/dividend/dividend_12.16.13

If you have questions or see something you think is inaccurate feel free to let me know.

Recs

0
Member Avatar jobe0722 (< 20) Submitted: 1/10/2014 3:29:28 PM : Underperform Start Price: $38.71 ABT Score: -5.14

Stock has not moved in years. Even in a Bull Market

Recs

0
Member Avatar chris293 (86.58) Submitted: 12/17/2013 6:50:50 PM : Outperform Start Price: $35.86 ABT Score: +11.33

A leading company for health and wealth.

Recs

0
Member Avatar timvan (< 20) Submitted: 11/28/2013 6:50:06 PM : Outperform Start Price: $37.47 ABT Score: +7.49

A nice dividend pay out and a P/E of 9.15, plus a strong line of nutritional products catching fire in the developing nations. This is a Core stock for me at the price it is at today.

Recs

0
Member Avatar 101JJP (48.31) Submitted: 11/23/2013 12:49:36 PM : Outperform Start Price: $37.54 ABT Score: +7.03

The Deal, a business unit of TheStreet, has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the sixth consecutive year. Abbott was recognized by The Deal as the best all-around dealmaker in healthcare.
Abbott has long recognized the global shifts in healthcare and has completed a number of strategic actions that have enhanced its diversity, product offerings and geographic reach to align with long-term health trends. This year, Abbott completed its most transformative event to date – separating its proprietary research-based pharmaceuticals business, creating an independent company named AbbVie.
"Healthcare needs have never been greater or more diverse," said Miles D. White, chairman and chief executive officer, Abbott. "We've anticipated these needs and through targeted licensing, M&A and internal R&D, we've reshaped the company so it is well positioned for continued success."
In the past five years, Abbott has completed a number of acquisitions and divestitures to bolster its best-in-class product portfolio and expand its global reach.
Separated its proprietary research-based pharmaceuticals business, creating two leading healthcare companies.
Acquired Advanced Medical Optics and OptiMedica, adding leading eye care technology to Abbott's diverse medical products portfolio and pipeline. Purchased Vistatek, an ophthalmic surgical distributor, expanding its vision care presence in Brazil and Latin America.
Gained access to the emerging field of non-surgical heart valve repair through the acquisition of Evalve and expanded its global peripheral artery disease technology portfolio with the purchase of IDEV Technologies.
Diversified its established pharmaceutical portfolio and gained access to key emerging markets through the acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions.
Acquired 3A Nutrition, a distributor in Vietnam, a key medical and pediatric nutrition market for Abbott.

Recs

0
Member Avatar HealthyMoney (< 20) Submitted: 10/25/2013 12:11:43 PM : Outperform Start Price: $36.42 ABT Score: +7.09

After spinning off AbbVie, Abbott can focus more on its diversity of revenue streams and less on strategizing for the impending loss of Humira patent protection.

Recs

0
Member Avatar coolmonies (55.94) Submitted: 8/7/2013 1:21:56 PM : Outperform Start Price: $35.02 ABT Score: +7.69

People are living longer, more old people=greater demand for drugs. Also abbot seems to be at the top of the drug company pyramid of power.

Recs

0
Member Avatar anchor68 (55.81) Submitted: 7/18/2013 7:24:53 PM : Outperform Start Price: $34.80 ABT Score: +8.03

Great pipeline

Recs

0
Member Avatar BrentonKJ (27.15) Submitted: 7/15/2013 3:46:29 PM : Outperform Start Price: $34.07 ABT Score: +9.45

More nimble and focused after split.

Recs

0
Member Avatar healthcarevalue (98.05) Submitted: 7/4/2013 3:37:33 PM : Outperform Start Price: $33.55 ABT Score: +8.35

Price/earnings good at 10.4, reasonable market cap at 53.39 Billion, Return on Invested Capital (ROIC) 13.18 last twelve trailing months, ROIC of over 10 percent going back to 2007, Low debt/equity ratio of 0.15. Abbott Laboratories has 91,000 employees and strong value in both its generic drug segment and diagnostic segments. Company initially founded in 1888 in Illinois.

Recs

0
Member Avatar cschweit (37.24) Submitted: 5/23/2013 4:32:40 PM : Outperform Start Price: $36.06 ABT Score: +0.41

Undervalued stock as of right now. Biggest growth will come from emerging markets. Will need to deliver to those emerging markets if it will succeed - which I think it can. A little woried about a major buy out of it's major branches not that it's a little more diversified than other companies in it's market. Still a strong company with a good future.

Recs

0
Member Avatar Teacherman333 (84.80) Submitted: 5/18/2013 4:32:52 PM : Outperform Start Price: $34.97 ABT Score: +3.36

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 25.53%
Trailing PE 11.15
PB 2.54
Div yield 1.50%

Recs

0
Member Avatar IfHeDiesHeDies (72.25) Submitted: 4/8/2013 7:22:33 PM : Outperform Start Price: $35.33 ABT Score: -3.42

A++

Recs

2
Member Avatar dreamjob (88.52) Submitted: 2/20/2013 6:05:10 AM : Outperform Start Price: $33.54 ABT Score: +0.60

My Abbot Haiku:

Sales and earnings grow
Free cash flow in abundance
Big player priced right

Recs

0
Member Avatar sirhc1978 (76.90) Submitted: 2/7/2013 10:37:56 AM : Outperform Start Price: $33.00 ABT Score: +0.17

BIG INSIDE BUY

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 2/2/2013 5:45:05 PM : Underperform Start Price: $32.25 ABT Score: -3.49

sp500 in maximums.

Featured Broker Partners


Advertisement